论文部分内容阅读
为研究牛包虫病基因工程亚单位疫苗EG95对牦牛的免疫效果、安全性,并调查该疫苗在不同性别、不同年龄、不同海拔地区牦牛间存在的免疫差异性。对4月龄及以上牦牛以免疫剂量每次1头份,每头份含EG95 250μg进行首免、加免(28d后)、安全评价(免疫剂量每次2头份含EG95 500μg),在试验前、首免后28d及加免后28d分别对免疫效果组和对照组牦牛采血,应用间接ELISA法检测血清中特异性抗体。结果显示,首免后28d免疫抗体群体阳性率为71.33%,加免后28d免疫抗体群体阳性率为83.00%,相比首免免疫抗体群体阳性率提高11.67%,与对照组、免疫前比较差异显著(P<0.05)。安全试验组牦牛免疫后第1天有6头出现精神沉郁、采食量下降、体温升高、注射部局部肿胀等不同程度免疫应激反应,4d后均恢复正常。石渠县、康定市不同海拔地区试验牦牛在免疫抗体产生时间、群体阳性率等方面,无明显差异(P>0.05)。结果表明,该疫苗适用于不同海拔地区牦牛使用,安全并可产生较高的抗体水平,对4月龄及以上牦牛免疫程序基本为2次免疫,分别颈部皮下注射1头份,间隔期28d。
In order to study the immune effect and safety of genetically engineered subunit vaccine EG95 against yak in bovine hydatid disease and investigate the immunological differences of the vaccine in yaks of different sexes, different ages and altitudes. Immunization dose (EG95 500μg for 2 doses) was used to immunize the yak at 4 months of age and above with 1 dose of EG95 250μg per head, Serum specific antibodies were detected by ELISA before and 28 days after the first immunization and 28 days after the immunization. The results showed that the positive rate of immunized antibody group was 71.33% 28 days after the first immunization, and the positive rate of immunized antibody group was 83.00% on the 28th day after immunization, compared with that of the first immunized antibody group (11.67%). Compared with the control group, Significant (P <0.05). On the first day after immunization, six rabbits in the safety test group showed psychotic depression, decreased feed intake, increased body temperature, and local swelling of the injection. Different degrees of immune stress reaction returned to normal after 4 days. There was no significant difference (P> 0.05) in the test yaks of Shiqu County and Kangding City at different elevations in terms of time of antibody production and population positive rate. The results showed that the vaccine was suitable for yaks at different altitudes, safe and could produce high antibody levels. Immunization procedures for yaks at 4 months of age and above were basically immunized twice, with 1 subcutaneous injection on the neck and an interval of 28 days .